Correction: The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy

Jian Cui; Lin Yang; Lei Guo; Yongfu Shao; Dongfeng Tan; Ni Li; Haizeng Zhang

doi:10.18632/oncotarget.26723

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy

PDF | How to cite

Oncotarget. 2019; 10:1539-1539. https://doi.org/10.18632/oncotarget.26723

Metrics: PDF 1587 views | ?

Jian Cui¹, Lin Yang², Lei Guo², Yongfu Shao¹, Dongfeng Tan³, Ni Li⁴ and Haizeng Zhang¹

¹ Department of Colorectal Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
² Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
³ Department of Pathology and Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
⁴ National Office for Cancer Prevention and Control, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Published: February 19, 2019

This article has been corrected: The correct author and affiliation information is given below:

Jian Cui¹, Lin Yang², Lei Guo², Yongfu Shao¹, Dongfeng Tan³, Ni Li⁴ and Haizeng Zhang¹

Original article: Oncotarget. 2017; 8:37845-37854. DOI: https://doi.org/10.18632/oncotarget.14708.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26723

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy